Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
570.55B
Market cap570.55B
Price-Earnings ratio
26.84
Price-Earnings ratio26.84
Dividend yield
2.26%
Dividend yield2.26%
Average volume
7.66M
Average volume7.66M
High today
$237.71
High today$237.71
Low today
$230.41
Low today$230.41
Open price
$232.34
Open price$232.34
Volume
8.35M
Volume8.35M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$149.04
52 Week low$149.04

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $237.26. The company's market cap stands at 570.55B, with a P/E ratio of 26.84 and a dividend yield of 2.3%.

On 2026-06-09, Johnson & Johnson(JNJ) stock traded between a low of $230.41 and a high of $237.71. Shares are currently priced at $237.26, which is +3.0% above the low and -0.2% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 8.35M, against a daily average of 7.66M.

During the past year, Johnson & Johnson(JNJ) stock moved between $149.04 at its lowest and $251.71 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $149.04 at its lowest and $251.71 at its peak.

JNJ News

24/7 Wall St. 12h
The Cash-Return Pivot: 5 Companies Hiking Dividends Right Now

The Cash-Return Pivot: 5 Companies Hiking Dividends Right Now By Jeremy Phillips Published Jun 9, 8:04AM EDT Quick Read Apple's $100 billion buyback authoriza...

The Cash-Return Pivot: 5 Companies Hiking Dividends Right Now
24/7 Wall St. 12h
A Portfolio That Doubles Your Social Security Check—and Your Spouse's

A Portfolio That Doubles Your Social Security Check—and Your Spouse’s By Drew Wood Published Jun 9, 7:36AM EDT Quick Read A $1.2M portfolio blending covered-c...

A Portfolio That Doubles Your Social Security Check—and Your Spouse's
New York Times 14h
Buy JJ Wetherholt, sell Christian Yelich, hold Ryan Weathers in fantasy baseball - The New York Times

...

Buy JJ Wetherholt, sell Christian Yelich, hold Ryan Weathers in fantasy baseball - The New York Times

Analyst ratings

68%

of 25 ratings
Buy
68%
Hold
28%
Sell
4%

More JNJ News

24/7 Wall St. 15h
Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes

Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes By Drew Wood Published Jun 9, 5:08AM EDT Quick Read Reaching $5,000...

Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes
The Wall Street Journal 1d
Johnson & Johnson to Buy Firefly Bio for $1 Billion

The New Brunswick, N.J., company said it expects to complete the acquisition later this year. brendan mcdermid / Reuters Johnson & Johnson JNJ 2.02 %increase;...

Johnson & Johnson to Buy Firefly Bio for $1 Billion
TipRanks 1d
M&A News: Johnson & Johnson Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

Johnson & Johnson (JNJ) stock was on the move Monday after the company said it will acquire Firefly Bio. The healthcare company will purchase the private biotec...

Nasdaq 1d
Johnson & Johnson To Acquire Firefly Bio To Expand Oncology Pipeline

(RTTNews) - Johnson & Johnson (JNJ) on Monday announced a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company for $1 billion in cash. Th...

Johnson & Johnson To Acquire Firefly Bio To Expand Oncology Pipeline
Simply Wall St 2d
Will Late-Stage Immunology and Oncology Wins Redefine Johnson & Johnson's Post-Biosimilar Narrative?

In early June 2026, Johnson & Johnson reported a series of positive late-stage data readouts and regulatory advances across its immunology and oncology pipeline...

Will Late-Stage Immunology and Oncology Wins Redefine Johnson & Johnson's Post-Biosimilar Narrative?
Nasdaq 3d
Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock

Key Points When Tylenol pills were tampered with and tainted in 1982, Johnson & Johnson managed the setback in stride. More recently, the healthcare giant has...

Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock
Simply Wall St 3d
Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story

Johnson & Johnson (NYSE:JNJ) reported multiple milestone clinical trial readouts at ASCO 2026 across autoimmunity, oncology, and myeloma. The company highlight...

Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.